GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Earnings Power Value (EPV)

Lifecore Biomedical (Lifecore Biomedical) Earnings Power Value (EPV) : $-12.25 (As of May23)


View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical Earnings Power Value (EPV)?

As of May23, Lifecore Biomedical's earnings power value is $-12.25. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Lifecore Biomedical Earnings Power Value (EPV) Historical Data

The historical data trend for Lifecore Biomedical's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Earnings Power Value (EPV) Chart

Lifecore Biomedical Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Earnings Power Value (EPV)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.44 -10.31 -10.40 -10.35 -12.25

Lifecore Biomedical Quarterly Data
Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.35 -11.62 -12.78 -12.98 -12.25

Competitive Comparison of Lifecore Biomedical's Earnings Power Value (EPV)

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical's Earnings Power Value (EPV) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Earnings Power Value (EPV) falls into.



Lifecore Biomedical Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Lifecore Biomedical's "Earning Power" Calculation:

Average of Last 20 Quarters Last Quarter
Revenue 256.4
DDA 17.1
Operating Margin % -3.74
SGA * 25% 11.2
Tax Rate % -13.45
Maintenance Capex 25.7
Cash and Cash Equivalents 19.1
Short-Term Debt 1.9
Long-Term Debt 110.8
Shares Outstanding (Diluted) 30.3

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = -3.74%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = $256.4 Mil, Average Operating Margin = -3.74%, Average Adjusted SGA = 11.2,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 256.4 * -3.74% +11.2 = $1.60355496 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = -13.45%, and "Normalized" EBIT = $1.60355496 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = 1.60355496 * ( 1 - -13.45% ) = $1.8192651732192 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 17.1 * 0.5 * -13.45% = $-1.147200012 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = 1.8192651732192 + -1.147200012 = $0.6720651612192 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Lifecore Biomedical's Average Maintenance CAPEX = $25.7 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Lifecore Biomedical's current cash and cash equivalent = $19.1 Mil.
Lifecore Biomedical's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 110.8 + 1.9 = $112.624 Mil.
Lifecore Biomedical's current Shares Outstanding (Diluted Average) = 30.3 Mil.

Lifecore Biomedical's Earnings Power Value (EPV) for May23 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( 0.6720651612192 - 25.7)/ 9%+19.1-112.624 )/30.3
=-12.25

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( -12.253631813437-6.52 )/-12.253631813437
= N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.


Lifecore Biomedical  (NAS:LFCR) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Lifecore Biomedical Earnings Power Value (EPV) Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical (Lifecore Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.
Executives
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318